Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 1

MACE + UA and MACE. Data presented for the overall population, the subgroup of patients with a history of CVD (CVD history) and the subgroup of elderly patients aged ≥65 years with a history of CVD and hypertension (Elderly patients with CVD risk). n is the number of patients with an event; N is the number of patients in treatment group. CI confidence interval, CTRL control, CVD cardiovascular disease, DAPA dapagliflozin, HR hazard ratio, MACE major adverse cardiovascular events (cardiovascular death, myocardial infarction and stroke), MACE + UA MACE plus unstable angina, p–y = patient years

Back to article page